Educational content, not medical advice. This article reports what the prescribing information for GLP-1 medicines says about hypersensitivity reactions. It does not diagnose any symptom, and it cannot tell any reader what a rash, a swelling or any other change means. Anything that worries you belongs with urgent care or your prescriber.

Every label in the GLP-1 class carries the same quiet paragraph. It sits inside Warnings and Precautions under the heading Hypersensitivity Reactions, and it appears on the label for Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Foundayo, generic liraglutide, generic exenatide and the two insulin combination products, Soliqua and Xultophy. Those products come from different companies, are injected or swallowed, and treat different conditions. On this one subject their paperwork agrees, nearly word for word.

That agreement is worth reading slowly, because the warning does three distinct jobs at once. It names the serious reactions reported with the medicine, it rules the medicine out for one group of people, and it raises a caution flag for a second group. If the structure of a prescribing information is unfamiliar, How to Read Your GLP-1's Prescribing Information walks through the numbered sections this warning lives in.

The paragraph every label carries

The core of the warning is the same everywhere. Each label states that serious hypersensitivity reactions have been reported, and each names anaphylaxis, some writing “anaphylactic reactions”, and angioedema as the serious reactions seen. Anaphylaxis is a severe, whole-body allergic reaction; angioedema is swelling that develops in deeper layers of tissue. Those two words carry the substance of the subsection, and no label in the class omits either one.

Then comes the hard rule, which sits in the Contraindications section at the front of the label rather than in the warning itself: the product is contraindicated in any patient with a serious hypersensitivity reaction to that active ingredient or to any of the excipients in that product. In label language, a contraindication is not a caution or a preference. It means the medicine is ruled out for that person, full stop, and the excipient clause matters because reactions can come from inactive ingredients rather than from the molecule itself.

Alongside the hard rule sits an open question, and the labels handle it with striking consistency. Each one instructs clinicians to use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist, because it is unknown whether such patients will be predisposed to these reactions with this product. The class-wide wording leaves the cross-product question deliberately unanswered: a serious reaction to one medicine rules out that medicine, and makes a different one a question for a prescriber rather than a conclusion either way.

What the label says to do

When a reaction occurs, the printed instruction is the same on every label: discontinue the product, treat the reaction promptly per standard of care, and monitor the patient until signs and symptoms resolve. Several of the labels add that the patient should promptly seek medical attention. Written for clinicians, the sentence still tells a reader the most useful thing there is to know: this is not a category of event anyone evaluates alone at home.

Nothing in this paragraph is a self-check list, and it should not be turned into one. A swelling, a rash, a feeling of something being wrong after a dose is a reason to get medical help now, by urgent care or by phone, and to let a clinician decide what it is. What a label can do is prepare you: knowing in advance that this warning exists, and that it names anaphylaxis and angioedema, means the sentence in the paperwork never arrives as a surprise in a moment when speed matters.

GLP 1 Tracker AppKeep a side effect diary with severity ratings so anything you do report to a clinician comes with dates and context, not memory. Get the app

Where the labels differ

The differences come in three layers. The first is pure navigation: the subsection number varies by product. The warning is 5.1 on Soliqua, 5.4 on Mounjaro and Trulicity, 5.6 on Foundayo and Zepbound, 5.7 on Victoza, Wegovy, Byetta and the semaglutide tablets, 5.8 on Ozempic and Saxenda, and 5.9 on Xultophy. That is a reading hazard rather than a medical one. Someone comparing a numbered warning across two labels may land on entirely different subjects and conclude the warnings differ, when in fact only the ordering does.

The second layer is the evidence the labels cite, and here the wording genuinely varies. Victoza, Trulicity, Saxenda and generic liraglutide attribute the reports to the postmarketing setting, meaning reports gathered after approval. Ozempic, Mounjaro and the semaglutide tablets say the reactions have been reported in patients treated with the product. Zepbound says reported postmarketing with tirzepatide. Foundayo, the newest of the group, attributes them to GLP-1 receptor agonists as a class rather than to orforglipron itself. Each sentence is doing careful, slightly different bookkeeping about where the reports came from, and none of them ranks one product against another.

The rates three labels print

Most labels in the class print no trial rate for these reactions at all. Three do. In a pool of its two trials, hypersensitivity reactions, including anaphylactic reaction, occurred in 0.5% of Foundayo-treated patients compared with 0.3% of placebo-treated patients. In the pool of placebo-controlled adult trials for Mounjaro, hypersensitivity reactions were reported in 3.2% of Mounjaro-treated patients compared with 1.7% on placebo, and that label calls them sometimes severe, giving urticaria and eczema as examples.

Zepbound's label is the most granular. Immediate hypersensitivity reactions, defined on that label as occurring within one day after drug administration, occurred in 2.1% of Zepbound-treated patients compared with 0.4% on placebo. Non-immediate reactions occurred in 3.5% compared with 2.7%. Severe hypersensitivity reactions occurred in 0.1% of Zepbound-treated patients and in no placebo-treated patients. The label adds that the majority of the hypersensitivity reactions in the trials were skin reactions such as rash and itching.

The tirzepatide labels add one more finding, reported for both Mounjaro and Zepbound: hypersensitivity reactions were more common in patients who developed anti-tirzepatide antibodies. In Mounjaro's pool of seven adult trials, 106 of 2,570 patients with those antibodies, or 4.1%, had hypersensitivity reactions, against 73 of 2,455 patients without them, or 3.0%. In Zepbound the figures were 6.2% against 3%. This is laboratory bookkeeping published for clinicians, one of the few places where the labels explain any of the variation at all.

Counted separately from injection site reactions

A hypersensitivity reaction and an injection site reaction are different entries on these labels, and the distinction is worth knowing before anyone reads a rate and attaches it to the wrong thing. Injection site reactions were reported in 0.2% of Ozempic-treated patients, 0.5% of Trulicity-treated patients, approximately 2% of Victoza-treated adults, and 3.2% of Mounjaro-treated patients against 0.4% on placebo. The oral products, Rybelsus, Ozempic tablets, Wegovy tablets and Foundayo, have no injection site at all. Lumps, itching and soreness at an injection site have their own subject, covered in Lumps, Itching and Injection-Site Reactions, and they are not what the hypersensitivity subsection is counting.

The two insulin combination products carry extra wording because of their insulin component. Xultophy's warning says that severe, life-threatening, generalized allergy including anaphylaxis, angioedema, bronchospasm, hypotension and shock can occur with insulins. On Soliqua, the hypersensitivity warning is 5.1, the first warning on the label, and it names both lixisenatide and insulin glargine. For anyone on a combination product, the extra sentences come from the insulin half of the pairing.

The warning is class-wide, the contraindication attaches to the specific product and its excipients, and the cross-product question is explicitly left open. A reader who has had a serious reaction to one of these medicines brings that history to a prescriber, in writing if possible. For the other warning every label carries, the one in the box at the top, read The Boxed Warning on Your GLP-1 Label, Explained, and for making sense of anything you experience along the way, see How to Track GLP-1 Side Effects (and What to Show Your Doctor).

Frequently asked questions

Do all GLP-1 medicines carry a hypersensitivity warning?

Yes. Every current US prescribing information in this class, from Ozempic and Wegovy through Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Foundayo and the insulin combination products, has a Hypersensitivity Reactions subsection inside Warnings and Precautions. Each names anaphylaxis and angioedema, and each contraindicates the product in anyone who has had a serious hypersensitivity reaction to its active ingredient or to any of its excipients.

Can I take a different GLP-1 after a reaction to one?

The labels leave that question open rather than answering it. Each one tells clinicians to use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist, because it is unknown whether such patients will be predisposed to these reactions with a different one. That is a decision for a prescriber with the full reaction history in front of them, never a guess made from a label.

How common are hypersensitivity reactions on GLP-1s?

Most labels print no trial rate at all. The ones that do: hypersensitivity reactions occurred in 0.5% of Foundayo-treated patients against 0.3% on placebo, and in 3.2% of Mounjaro-treated patients against 1.7% on placebo. For Zepbound, immediate reactions, defined as within one day after administration, occurred in 2.1% against 0.4% on placebo, non-immediate reactions in 3.5% against 2.7%, and severe reactions in 0.1% against none.

Is an injection site reaction the same as a hypersensitivity reaction?

No. The labels count them separately. Injection site reactions were reported in 0.2% of Ozempic-treated patients, 0.5% of Trulicity-treated patients, approximately 2% of Victoza-treated adults and 3.2% of Mounjaro-treated patients against 0.4% on placebo, and the oral products have no injection site at all. Anything at an injection site that concerns you belongs with your prescriber, same as any other reaction.

What does the label say to do if a reaction occurs?

The instruction is the same across the class: discontinue the product, treat the reaction promptly per standard of care, and monitor the patient until signs and symptoms resolve. Several labels add that the patient should promptly seek medical attention. Translated out of label language, that means anything worrying gets urgent care or a call to the prescriber right away, not a wait to see whether it passes.